To investigate the heterogeneity of murine CT26 tumor treated with hsBCL9CT-24 and genetically depleted Bcl9, we conducted single-cell mRNA sequencing in 12 samples (see Materials and Methods). This evidence concerns the gene BCL9 and neoplasm.